HUMAN METABOLISM AND DISPOSITION OF DAPRODUSTAT: A PROLYL HYDROXYLASE INHIBITOR TO TREAT ANEMIA IN CHRONIC KIDNEY DISEASE (CKD).

被引：0
|
作者：
Chen, L. [1 ]
Xia, F. [1 ]
Chen, C. [1 ]
Felgate, C. [2 ]
Pereira, A. [3 ]
Pirhalla, J. [1 ]
Miao, X. [1 ]
Young, G. [3 ]
Beaumont, C. [3 ]
Tai, G. [1 ]
机构：
[1] GlaxoSmithKline, Collegeville, PA USA
[2] GMX, Ware, Herts, England
[3] GlaxoSmithKline, Ware, Herts, England
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2021年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIII-035
引用
收藏
页码：S54 / S54
页数：1
相关论文
共 50 条
  • [1] Daprodustat: A Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia of Chronic Kidney Disease
    Johnson, Haley N.
    Prasad-Reddy, Lalita
    [J]. ANNALS OF PHARMACOTHERAPY, 2024,
  • [2] Daprodustat Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor Treatment of anemia associated with chronic kidney disease
    Gras, J.
    [J]. DRUGS OF THE FUTURE, 2017, 42 (06) : 327 - 333
  • [3] Population Kinetic/Pharmacodynamic (K/PD) Analyses of Daprodustat (Prolyl Hydroxylase Inhibitor) in Non-dialysis (ND) and Hemodialysis-Dependent (HDD) Anemia Patients with Chronic Kidney Disease (CKD)
    Mahar, Kelly M.
    Johnson, Brendan
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S64 - S64
  • [4] Prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease
    Cases, A.
    Vera, M.
    Ojeda, R.
    Gorriz, J. L.
    [J]. DRUGS OF THE FUTURE, 2018, 43 (01) : 23 - 33
  • [5] Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease
    Kurata, Yu
    Tanaka, Tetsuhiro
    Nangaku, Masaomi
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2020, 29 (04): : 414 - 422
  • [6] Daprodustat (Jesduvroq) for Anemia of Chronic Kidney Disease
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2024, 66 (1696): : 25 - 27
  • [7] Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease
    McMahon, Gearoid M.
    Singh, Ajay K.
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2019, 28 (06): : 600 - 606
  • [8] Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence
    Fujikawa, Ryo
    Nagao, Yuji
    Fujioka, Masaki
    Akizawa, Tadao
    [J]. THERAPEUTIC APHERESIS AND DIALYSIS, 2022, 26 (04) : 679 - 693
  • [9] Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease
    Sakashita, Midori
    Tanaka, Tetsuhiro
    Nangaku, Masaomi
    [J]. CKD-ASSOCIATED COMPLICATIONS: PROGRESS IN THE LAST HALF CENTURY, 2019, 198 : 112 - 123
  • [10] Influence of acute and chronic kidney failure in rats on the disposition and pharmacokinetics of ZYAN1, a novel prolyl hydroxylase inhibitor, for the treatment of chronic kidney disease-induced anemia
    Patel, Harilal
    Joharapurkar, Amit Arvind
    Pandya, Vrajesh Bhaskarbhai
    Patel, Vishal Jagjivanbhai
    Kshirsagar, Samadhan Govind
    Patel, Prakash
    Gevriya, Bhavesh
    Jain, Mukul R.
    Srinivas, Nuggehally R.
    Patel, Pankaj Ramanbhai
    Desai, Ranjit C.
    [J]. XENOBIOTICA, 2018, 48 (01) : 37 - 44
12345